For lung adenocarcinoma and for clear cell renal cell carcinoma, PBRM1 mutational status was found to be a negative prognostic marker, while for colon adenocarcinoma, gastric cancer, and uterine corpus endometrial carcinoma, PBRM1 mutations were found to be a positive predictive marker for immunotherapy38. This evidence concerns the gene PBRM1 and uterine corpus endometrial carcinoma.